Citizens Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $22
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Citizens analyst Daniel Stauder maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the price target from $25 to $22.
Citizens analyst Daniel Stauder maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the price target from $25 to $22.